December 11th, 2017
jobs
homes

Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

IDEAYA Biosciences, Inc. - Common Stock (NQ:IDYA)

37.10 +0.93 (+2.57%)
Streaming Delayed Price Updated: 1:22 PM EDT, Jul 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about IDEAYA Biosciences, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
News headline image
IDEAYA Biosciences Spotlights Darovasertib Win, FDA Review Path at Oncology Summit ↗
IDEAYA Biosciences (NASDAQ:IDYA) executives highlighted recent clinical progress across the company’s oncology pipeline during a fireside chat at TD Cowen’s seventh annual Oncology Innovation Summit,... 
Via MarketBeat
News headline image
IDEAYA Biosciences Eyes Busy 2026 as Darovasertib Advances Toward FDA Filing ↗
IDEAYA Biosciences (NASDAQ:IDYA) Chief Executive Yujiro Hata said the precision oncology company is preparing for a busy 2026, led by regulatory and clinical milestones for darovasertib in metastatic... 
Via MarketBeat
News headline image
IDEAYA Biosciences Says Melanoma Drug on Track for NDA After Strong Trial Data ↗
IDEAYA Biosciences (NASDAQ:IDYA) said its lead oncology program remains on track for a regulatory submission after reporting positive top-line data in first-line metastatic melanoma, while also... 
Via MarketBeat
News headline image
A Cancer Antigen Long Thought Untouchable Is Suddenly the Hottest Target in Oncology
From USA News Group
Via GlobeNewswire
News headline image
Why IDEAYA Biosciences Shares Are Trading Higher By 18%; Here Are 20 Stocks Moving Premarket ↗
IDEAYA Biosciences shares (NASDAQ: IDYA) jumped 18% in pre-market trading after announcing topline results from ongoing Phase 2/3 trial. 
Via Benzinga
News headline image
Get insights into the top gainers and losers of Friday's after-hours session. ↗
The regular session of the US market on Friday is now over, but let's get a preview of the after-hours session and explore the top gainers and losers driving the post-market movements. 
Via Chartmill
News headline image
A Healthcare Hedge Fund Just Added $24.5 Million in Immunovant Stock. Should you? ↗
This clinical-stage biotech develops antibody therapies targeting autoimmune diseases, with a lead candidate in Phase II trials. 
Via The Motley Fool
A Whole Watchlist of “Coiled Springs” (Found With One Simple ChartMill Screen) ↗
Via Chartmill
News headline image
IDEAYA Biosciences Inc (NASDAQ:IDYA) Shows Strong Technical Setup for Potential Breakout ↗
IDEAYA Biosciences (IDYA) shows strong technical health and a high-quality breakout setup, indicating potential for a continued advance. 
Via Chartmill
News headline image
SLB To Rally Around 44%? Here Are 10 Top Analyst Forecasts For Tuesday ↗
 
Via Benzinga
News headline image
Buying IDEAYA Might Be The Wrong IDYA Right Now ↗
IDEAYA Stock's Adhishthana.com cycle signals prolonged weakness after a failed Cakra, with underperformance likely until May 2029. 
Via Benzinga
News headline image
Alibaba To Rally Around 35%? Here Are 10 Top Analyst Forecasts For Tuesday ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Friday's After-Market Session ↗
 
Via Benzinga
News headline image
IDEAYA (IDYA) Q2 Net Loss Improves 27% ↗
Via The Motley Fool
Topics Intellectual Property
News headline image
This Royal Caribbean Cruises Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Tuesday ↗
 
Via Benzinga
News headline image
This Trade Desk Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Thursday ↗
 
Via Benzinga
News headline image
This NRG Energy Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday ↗
 
Via Benzinga
News headline image
Jim Cramer Says This Tobacco Stock Is 'Undervalued' But He's Not Recommending It ↗
Altria Group is "undervalued," Cramer says. On Oct. 31, the company reported third-quarter adjusted earnings per share of $1.38. 
Via Benzinga
News headline image
Biocytogen Announces IDEAYA’s Nomination of Development Candidate IDE034, a Potential First-in-Class B7H3/PTK7 Topo-I-Payload Bispecific ADC and Option Exercise
From Biocytogen Pharmaceuticals (Beijing) Co., Ltd.
Via Business Wire
News headline image
This Cognex Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday ↗
 
Via Benzinga
News headline image
Ideaya Biosciences Stock Tumbles Despite Promising Data From Rare Eye Cancer Candidate ↗
IDEAYA Biosciences released interim Phase 2 data that shows promising tumor shrinkage and eye preservation rates. 
Via Benzinga
News headline image
Oracle To Rally Around 29%? Here Are 10 Top Analyst Forecasts For Tuesday ↗
 
Via Benzinga
News headline image
IDYA Stock Earnings: IDEAYA Biosciences Misses EPS for Q2 2024 ↗
IDYA stock results show that IDEAYA Biosciences missed analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
News headline image
Week In Review: ImmuneOnco Out-Licenses Two Antibodies In $2 Billion Deal ↗
Shanghai ImmuneOnco Biopharma out-licensed global rites (ex-China) for two of its antibodies to Instil Bio of Dallas, Texas. ImmuneOnco will receive an upfront and near-term payments of $50 million,... 
Via Talk Markets
News headline image
MarketBeat Week in Review – 7/15 - 7/19
Stocks took a breather to close the week, but corporate earnings and the next reading on the PCE index will help determine what direction the market moves next 
Via MarketBeat
Topics Economy
News headline image
Positive News is Driving This Cancer Drug Maker’s Stock Higher
IDEAYA Biosciences stock is up more than 16% on positive treatment data in a Phase 2 clinical trial, but after a 76% run-up, IDYA stock may need a breather 
Via MarketBeat
News headline image
Why SeaStar Medical Holding Shares Are Trading Lower By Around 34%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session ↗
 
Via Benzinga
News headline image
Kura Sushi Posts Weak Q3 Results, Joins LegalZoom.com And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Why Arhaus Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗
 
Via Benzinga
News headline image
IDEAYA Biosciences Highlights 'Encouraging' Preliminary Efficacy, Safety Profile For Patients With Hard-To-Treat Cancer ↗
IDEAYA Biosciences reports promising Phase 2 clinical data for IDE397 in MTAP-deletion urothelial and NSCLC patients. The study shows a 39% overall response rate, 94% disease control rate, and a... 
Via Benzinga
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

More ways to get to us

Lethbridge Herald Facebook Facebook
Lethbridge Herald Twitter Twitter
Lethbridge Herald YouTube YouTube

About Us

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

© 1996-2017 The Lethbridge Herald, A Division of Continental Newspapers Canada Ltd.